Entrada Therapeutics Temettü
Temettü kriter kontrolleri 0/6
Entrada Therapeutics does not have a record of paying a dividend.
Anahtar bilgiler
n/a
Temettü verimi
-16.6%
Geri Alım Getirisi
| Toplam Hissedar Getirisi | -16.6% |
| Gelecekteki Temettü Verimi | 0% |
| Temettü Büyümesi | n/a |
| Bir sonraki temettü ödeme tarihi | n/a |
| Eski temettü tarihi | n/a |
| Hisse başına temettü | n/a |
| Ödeme oranı | n/a |
Son temettü güncellemeleri
Güncelleme yok
Recent updates
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding
Oct 17
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher
Aug 23Entrada Therapeutics: A Complicated Tale
Jun 16Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry
May 29These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
Mar 19This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Nov 09Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
May 26Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 14Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Aug 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31Ödemelerde İstikrar ve Büyüme
Temettü verilerini getirme
İstikrarlı Temettü: Insufficient data to determine if TRDA's dividends per share have been stable in the past.
Büyüyen Temettü: Insufficient data to determine if TRDA's dividend payments have been increasing.
Piyasaya Karşı Temettü Getirisi
| Entrada Therapeutics Piyasaya Karşı Temettü Getirisi |
|---|
| Segment | Temettü Verimi |
|---|---|
| Şirket (TRDA) | n/a |
| Pazarın Alt %25'i (US) | 1.5% |
| Pazarın En İyi %25'i (US) | 4.5% |
| Sektör Ortalaması (Biotechs) | 2.2% |
| Analist tahmini (TRDA) (3 yıla kadar) | 0% |
Önemli Temettü: Unable to evaluate TRDA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Yüksek Temettü: Unable to evaluate TRDA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Hissedarlara Ödenen Kazanç
Kazanç Kapsamı: Insufficient data to calculate TRDA's payout ratio to determine if its dividend payments are covered by earnings.
Hissedarlara Nakit Ödeme
Nakit Akışı Kapsamı: Unable to calculate sustainability of dividends as TRDA has not reported any payouts.